Press releases

Date	Title	View
August 13, 2026	Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update	PDF Version
June 29, 2026	Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference	PDF Version
June 11, 2026	Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026	PDF Version
June 11, 2026	Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting	PDF Version
May 27, 2026	Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference	PDF Version
May 13, 2026	Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference	PDF Version
May 12, 2026	Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting	PDF Version
May 7, 2026	Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update	PDF Version
May 5, 2026	Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference	PDF Version
March 31, 2026	Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy	PDF Version